Amphastar Pharmaceuticals, Inc.
AMPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001297184
In the last 90 days, Amphastar Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 212 institutions reported holding it in 13F filings for Q2 2026, worth $572.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $763.9K in total
- 5
- 13F holdersQ2 2026, 0 vs. previous quarter
- 212
- 13F valueReported value at the end of Q2 2026
- $572.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AMPH, Q2 2026
No superinvestor reported holding AMPH at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Amphastar Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)6:02 PM ET | Sep 21 | 2 days | Peters William JCFO, EVP & TREASURER | SSale | −4.14K | $25.00 | −$103.5K | −2.4%168.7K after | 10b5-1 |
| Sep 17, 2026 (view filing)6:19 PM ET | Sep 16 | 1 day | Zhou RongSENIOR EVP, PRODUCTION CENTER | SSale | −10.0K | $23.94 | −$239.4K | −5.6%169.2K after | |
| Sep 3, 2026 (view filing)7:42 PM ET | Sep 2 | 1 day | Zhou RongSENIOR EVP, PRODUCTION CENTER | SSale | −3.19K | $23.63 | −$75.3K | −1.8%169.2K after | |
| Aug 12, 2026 (view filing)6:14 PM ET | Aug 11 | 1 day | Prins Richard KDirector | SSale | −7.97K | $20.30 | −$161.9K | −21.2%29.6K after | |
| Aug 11, 2026 (view filing)4:57 PM ET | Aug 7 | 4 days | Peters William JCFO, EVP & TREASURER | SSale | −8.18K | $22.48 | −$183.9K | −4.5%172.8K after | 10b5-1 |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Zhou RongSENIOR EVP, PRODUCTION CENTER | SSale | −9.79K | $26.20 | −$256.4K | −6.6%138.0K after | |
| Dec 15, 2025 (view filing) | Dec 11-12 | 4 days | Petersen Floyd F.Director | SSale | −4.16K | $25.82 | −$107.5K | −5.5%71.4K after | 2 lots |
| Nov 25, 2025 (view filing) | Nov 25 | Same day | Prins Richard KDirector | SSale | −4.18K | $27.10 | −$113.3K | −10.6%35.2K after | |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Petersen Floyd F.Director | SSale | −16.7K | $26.49 | −$441.8K | −18.1%75.5K after | |
| Nov 5, 2025 (view filing) | Nov 3 | 2 days | Petersen Floyd F.Director | SSale | −500 | $25.27 | −$12.6K | −0.7%75.5K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Amphastar Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,224,934 | $105.4M | 0.00% | −196,409−3.6% | Reduced |
| Dimensional Fund Advisors LP | 2,305,107 | $46.5M | 0.01% | +277,160+13.7% | Added |
| State Street Corp | 1,642,126 | $33.1M | 0.00% | +34,611+2.2% | Added |
| Vanguard Capital Management LLC | 1,481,952 | $29.9M | 0.00% | −61,703−4.0% | Reduced |
| American Century Companies Inc | 1,176,626 | $23.7M | 0.01% | +159,088+15.6% | Added |
| Marshall Wace, LLP | 1,066,322 | $21.5M | 0.02% | +40,682+4.0% | Added |
| Geode Capital Management, LLC | 969,840 | $19.6M | 0.00% | −6,810−0.7% | Reduced |
| Fuller & Thaler Asset Management, Inc. | 949,238 | $19.2M | 0.05% | −445,901−32.0% | Reduced |
| D. E. Shaw & Co., Inc. | 887,048 | $17.9M | 0.01% | +221,506+33.3% | Added |
| Vanguard Portfolio Management LLC | 809,568 | $16.3M | 0.00% | +21,752+2.8% | Added |